“Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw

Abu-Id, Mario Hakim; Warnke, Patrick H.; Gottschalk, Jack A.; Springer, Ingo N.; Wiltfang, Jens; Açil, Yahya; Russo, Paul; Kreusch, Thomas

doi:10.1016/j.jcms.2007.06.008

Cited by 194 publications

(166 citation statements)

References 74 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Vakaların %67'si mandibulada, %26'sı maksillada; %8'i ise her iki çenede birden görülmüştür. Maksillanın vaskülarizasyonunun mandibuladan daha fazla olmasının; mandibulada maksilladan daha fazla osteonekroz görülmesinin sebebi olabileceği bildirilmiştir 13 .…”

Section: Discussionunclassified

See 1 more Smart Citation

Oral bisphosphonate induced osteonecrosis of the jaw causing pathological mandibular fracture: literature review and a case report

Duygu¹,

Ülker²,

Cabbar³

et al. 2016

Yeditepe J Dent

View full text Add to dashboard Cite

Section: Discussionunclassified

“…Literatürde bildirilen İÇKON'a bağlı patolojik kırık olgusu az olduğundan dolayı tedavi yaklaşımları ile ilgili de az bilgi bulunmaktadır 13,20 .…”

Section: Discussionunclassified

Oral bisphosphonate induced osteonecrosis of the jaw causing pathological mandibular fracture: literature review and a case report

Duygu¹,

Ülker²,

Cabbar³

et al. 2016

Yeditepe J Dent

View full text Add to dashboard Cite

“…La plupart de ces études rapportent des cas uniques ou des séries de cas relativement peu importantes dont les résultats sont totalement contradictoires. Selon les publications, on arrive à l'une des conclusions suivantes : -l'OHB a un effet bénéfique sur le traitement des ONM [2,7,22,28,32,37,[50][51][52][53][54][55] entrainant une diminution de la taille et du nombre de foyers d'ostéonécrose, et une cicatrisation plus rapide ; -aucune conclusion n'est possible [9,31,56,57] ; -l'OHB n'a aucun impact bénéfique sur les ONM [20,[58][59][60][61][62][63][64].…”

Section: Résultats De L'utilisation De L'ohb Dans Le Traitement Des Ounclassified

Intérêt de l’oxygénothérapie hyperbare dans la prévention et le traitement des ostéonécroses des maxillaires dues aux bisphosphonates

Gunepin

Derache

Cathelinaud

et al. 2013

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Résumé -Les bisphosphonates (BP) sont des inhibiteurs du remodelage osseux indiqués dans la prise en charge de pathologies malignes (myélome multiple, métastases de tumeurs solides, etc.) et bénignes (ostéoporose, maladie de Paget, etc.). Depuis 2003, un effet indésirable imputé à cette classe de médicaments est apparu dans la littérature : les ostéonécroses des maxillaires (ONM) induites par la prise de BP. Cliniquement, l'ONM se caractérise par une exposition d'os nécrotique qui persiste pendant plus de 8 semaines. En 2007, puis 2009, l'American Association of Oral and Maxillofacial Surgeons (AAOMS) a émis des recommandations destinées aux professionnels de santé pour prévenir et prendre en charge cet effet indésirable. Cependant, l'absence de thérapeutiques efficaces a poussé de nombreux auteurs à tester, en complément des thérapies proposées par l'AAOMS, des traitements expérimentaux au nombre desquels figure l'oxygénothérapie hyperbare (OHB). D'un point de vue théorique, l'étiopathogénie des ONM n'étant pas connue, l'impact de l'OHB sur les mécanismes de survenue de cette pathologie reste hypothétique. D'un point de vue clinique, les avis divergent sur l'intérêt de l'utilisation de l'OHB dans le traitement des ONM. Cependant, les résultats préliminaires de deux essais cliniques contrôlés et randomisés en cours aux Etats-Unis laissent à penser que l'OHB pourrait trouver de nouvelles indications en chirurgie orale dans le traitement mais aussi la prévention des ONM.Abstract -Interest of hyperbaric oxygen therapy in the prevention and treatment of bisphosphonate-related osteonecrosis of the jaws. Bisphosphonates (BP) have been used since 1960s for their capability to alter the mechanism of bone resorption and remodeling. Intravenous (IV) BP are effective in the treatment and management of cancer-related conditions including hypercalcemia of malignancy, skeletal-related events associated with bone metastases in the context of solid tumors such as breast cancer, prostate cancer and lung cancer, and management of lytic lesions in the setting of multiple myeloma. Oral BP are used to treat osteoporosis and osteopenia. In 2003, oral and maxillofacial surgeons first recognized and reported cases of non-healing exposed bone in the maxillofacial region in patients treated with IV bisphosphonates. This adverse effect was called BONJ for bisphosphonate-related osteonecrosis of the jaws. Clinically, BONJ is defined by an exposed bone in the maxillofacial region that has persisted for more than 8 weeks. So far, the etiopathogenesis of BONJ remains

show abstract

“…This aside, mild cases of asymptomatic denuded bone very likely remain unidentified 5 . Most incidences of BRONJ have been reported as a result of intravenous administration of high doses of aminobisphosphonates indicated mostly in oncologic patients 6 . The association of BRONJ and non-nitrogen bisphosphonates is very rare 7 .…”

Section: Introductionmentioning

confidence: 99%

“…The association of BRONJ and non-nitrogen bisphosphonates is very rare 7 . The risk of BRONJ development in patients receiving low doses of bisphosphonates orally mainly for the treatment of postmenopausal osteoporosis is relatively low 6,8 . According to the American Association of Oral and Maxillofacial Surgeons, the disease is defined as the presence of an area of exposed necrotic bone in the maxillofacial region lasting for more than eight weeks in a patient who was receiving bisphosphonate and had not received radiation therapy to the craniofacial region 9 .…”

Section: Introductionmentioning

confidence: 99%

Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw

Janovska¹,

Mottl²,

Slezák³

2015

BIOMED PAP

View full text Add to dashboard Cite

“Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw

Cited by 194 publications

References 74 publications

Oral bisphosphonate induced osteonecrosis of the jaw causing pathological mandibular fracture: literature review and a case report

Oral bisphosphonate induced osteonecrosis of the jaw causing pathological mandibular fracture: literature review and a case report

Intérêt de l’oxygénothérapie hyperbare dans la prévention et le traitement des ostéonécroses des maxillaires dues aux bisphosphonates

Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw

Contact Info

Product

Resources

About